Teriparatide
Teriparatide is a peptide, indexed here under Endocrine and immune signalling peptides.
Identity
| Field | Value |
|---|---|
| Classification | Peptide |
| Primary class | Endocrine and immune signalling peptides |
| CAS registry number | 52232-67-4[1] |
| PubChem CID | 16133850[1] |
| UniProt accession | Unknown No UniProt query was run in v1. |
| Molecular formula | C181H291N55O51S2[1] |
| Molecular weight | 4118 g/mol[1] |
| Amino-acid sequence | Unknown Not reported by the PubChem property set retrieved for this record; no sequence database query was run in v1. |
| Reported half-life | Unknown No pharmacokinetics source was retrieved in v1. PubChem does not carry half-life as a property, so this is recorded as not yet sourced rather than estimated. |
What the cited literature examines
Teriparatide is the recombinant 1-34 fragment of human parathyroid hormone. The Drugs@FDA register returned approved applications under this generic name; those products are recorded in the regulatory status field and are not what this page describes. A 2005 Endocrine Reviews article reviews the evidence for parathyroid hormone and teriparatide in osteoporosis, and a 2003 Journal of Bone and Mineral Research paper reports cortical and cancellous bone structure under the peptide.
The retrieved records are osteoporosis trials: a 2003 Journal of Bone and Mineral Research paper on bone density in men, 2004 and 2005 papers on differential effects after raloxifene or alendronate and on bone remodelling compared with alendronate, a 2007 New England Journal of Medicine comparison with alendronate in glucocorticoid-induced osteoporosis, a 2010 Journal of Bone and Mineral Research randomised double-blind study of fracture repair, the 2013 Lancet DATA study with denosumab, the 2015 Lancet DATA-Switch extension, the 2017 Lancet comparison with romosozumab, and the 2018 Lancet VERO trial against risedronate in postmenopausal women with severe osteoporosis.
[3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13]Reported mechanism
A parathyroid hormone receptor agonist; the retrieved records report anabolic effects on bone remodelling that differ in direction from bisphosphonates.
[7, 4]Stated in the titles of the cited 2005 Archives of Internal Medicine and 2003 Journal of Bone and Mineral Research papers.
Targets named in the cited records: parathyroid hormone 1 receptor.
FDA application register
A query of the FDA Drugs@FDA application register on 2026-10-09 returned 3 application record(s) for this compound name (including ANDA213641, NDA211939, NDA021318, marketed as TERIPARATIDE, BONSITY, FORTEO). Material supplied as a research chemical is not the subject of those applications and is not an FDA-approved product.[2]
Scope statement: this records the result of a single automated query against the openFDA drugsfda endpoint on the stated date. It is not legal advice and is not a jurisdiction-by-jurisdiction legality assessment.
Retrieved 2026-10-09.
Amounts reported in the cited literature
Unknown. No retrieved record in this dataset states an amount, so none is shown. Where an amount is recorded it is what a named study reported administering in its own stated model, in the past tense, and is not a protocol.
No study-reported dose was taken from a source read in v1. Literature-reported values are only recorded where the retrieved citation metadata states the figure.
Adverse effects reported in the cited literature
Unknown. No retrieved record in this dataset reports an adverse effect for this compound, so no row is shown. Absence of a row records the absence of a retrieved report, nothing more.
No adverse-effect row was taken from a source read in v1. Rows are only recorded with the study model named and the reporting citation attached.
Other names
Teriparatide appears under these other names in the cited records or in common usage. Each one resolves to this page rather than to a separate page of its own.
- PTH (1-34)
- recombinant human parathyroid hormone (1-34)
- Forteo
Where this page sits
Research records
Cited research records for Teriparatide, each with its identifier, the publication type it is indexed as, and the study model stated by its assigned subject headings.
Compounds indexed next to it
- Somatostatin — Endocrine and immune signalling peptides
- Oxytocin — Endocrine and immune signalling peptides
Class page: Endocrine and immune signalling peptides. Full index: all indexed compounds.
Questions this page answers
What does the cited literature examine for Teriparatide?
Teriparatide is the recombinant 1-34 fragment of human parathyroid hormone. The Drugs@FDA register returned approved applications under this generic name; those products are recorded in the regulatory status field and are not what this page describes.
Which class is Teriparatide indexed under?
Teriparatide is indexed under Endocrine and immune signalling peptides. This class groups peptides whose retrieved literature concerns endocrine or immune signalling outside the growth hormone axis.
What does the FDA application register show for Teriparatide?
A query of the FDA Drugs@FDA application register on 2026-10-09 returned 3 application record(s) for this compound name (including ANDA213641, NDA211939, NDA021318, marketed as TERIPARATIDE, BONSITY, FORTEO). Material supplied as a research chemical is not the subject of those applications and is not an FDA-approved product.
Sources
- PubChem Compound Summary for CID 16133850, Teriparatide. PubChem, National Library of Medicine (2026). pubchem:16133850
- Drugs@FDA application register query for this compound, 3 application(s) returned: ANDA213641, NDA211939, NDA021318. U.S. Food and Drug Administration, openFDA drugsfda endpoint (2026). fda:teriparatide
- Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. Endocrine reviews (2005). pmid:15769903
- Recombinant human parathyroid hormone (1-34) [teriparatide] improves both cortical and cancellous bone structure. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research (2003). pmid:14606504
- The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research (2003). pmid:12510800
- Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research (2004). pmid:15068497
- Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass. Archives of internal medicine (2005). pmid:16087825
- Teriparatide or alendronate in glucocorticoid-induced osteoporosis. The New England journal of medicine (2007). pmid:18003959
- Teriparatide for acceleration of fracture repair in humans: a prospective, randomized, double-blind study of 102 postmenopausal women with distal radial fractures. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research (2010). pmid:19594305
- Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial. Lancet (London, England) (2013). pmid:23683600
- Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial. Lancet (London, England) (2015). pmid:26144908
- Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial. Lancet (London, England) (2017). pmid:28755782
- Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet (London, England) (2018). pmid:29129436
On each stated value was matched to the record cited for it. That is record matching, not an appraisal of the research. Compiled and checked by: Peptide Monographs editorial desk. No qualified clinical reviewer.